Search

Your search keyword '"Hamstra, Daniel"' showing total 631 results
Start Over Author "Hamstra, Daniel"
631 results on '"Hamstra, Daniel"'

2. Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp Trial

Author

Godette, Karen D., Patel, Sagar, Langen, Katja M., Zielan, Ryan R., DeBlois, David, Pang, Dalong, Rudra, Sonali, Benhabib, Sidi, Chawla, Ashish, Chen, Kuanling, Dadkhah, Hossein, Majithia, Lonika, Rao, Avani D., Stephenson, Lisa, Wang, Peng, Croog, Victoria J., Li, Heng, Smith, Karen, Stinson, Susan, Walker, Amanda J., Devisetty, Kiran, Hyde, Christian, Depauw, Nicholas, Godishala, Anuradha, Ho, Alice, Paganetti, Harald, Soto, Daniel, Suero-Abreu, Giselle, Taghian, Alphonse G., Corbin, Kimberly S., Halyard, Michele Y., Jackson, Amanda, Liang, Xiaoying, Manke, Heather, McGee, Lisa A., Pafundi, Deanna H., Remmes, Nicholas B., Shumway, Dean A., Yan, Elizabeth S., Bakhoum, Samuel F., Barron, David A., Bernstein, Michael, Cuaron, John J., Dover, Laura, Gelblum, Daphna Y., Gilbo, Philip, Gewanter, Richard M., Guttman, David M., Hong, Linda, Khan, Atif, LaPlant, Quincey, Mann, Justin, McCormick, Beryl, Mueller, Boris A., Mychalczak, Borys, Parikh, Dhwani, Powell, Simon N., Romesser, Paul B., Roth O'Brien, Diana, Schupak, Karen D., Shepherd, Annemarie F., Xu, Amy, Yu, Anthony, Zinovoy, Melissa, Bennouna, Jaafar, Fagundes, Marcio, Panoff, Joseph, Amelia Rodrigues, Maria, Yu, Jen, Lee, Choonsik, Chen, Chin-Cheng, Choi, J. Isabelle, Lin, Haibo, Akthar, Adil S., Akhter, Nausheen, Mihalcik, Stephen A., Pankuch, Mark, Parhar, Preeti K., Stutz, Michael D., Thukral, Arpi D., Mah, Dennis, Tsai, Henry K., Paulus, Rebecca, Haffty, Bruce G., Goyal, Sharad, Yue, Ning J., Sturgeon, Jared D., Wilkinson, J. Ben, Boggs, D. Hunter, Cardan, Rex A., Dalton, Allison, McDonald, Andrew, Prior, Fred, Mayadev, Jyoti S., Moiseenko, Vitali, Narezkina, Anya, Phreaner, Nicholas, Rash, Dominique, Seibert, Tyler, Yashar, Catheryn, Daugherty, Emily C., Mascia, Anthony, Medek, Sara A., Meier, Teresa, Bradley, Julie A., Lockney, Natalie, Mailhot, Raymond B., Mendenhall, Nancy, Rutenberg, Michael, Harris, Eleanor E., Lyons, Janice, Hong, Jack J., Kunaprayoon, Dan K., McAvoy, Sarah A., Manu Mysore, Nowak Choi, Kamila A., Patel, Akshar N., Vyfhuis, Melissa A.L., Wilson, Joelle, Algan, Ozer, Chen, Yong, Henson, Christina E., Dvorak, Tomas, Willoughby, Twyla, Zeidan, Omar, Berman, Abigail T., Chen, Et-tsu, Dong, Lei, Driscoll, Amanda, Feigenberg, Steven J., Feriozzi, Ashley, Hencek, Carolyn, Kolker, James D., Konski, Andre A., Ky, Bonnie, Lin, Lilie L., Novick, Kristina L., Reza, Nosheen, Siegal, Ann Marie, Tabakha, Sara, Taunk, Neil K., Wilcox, Nicholas, Zou, Wei, Bhooshan, Neha, Croley, Richard, Weksberg, David C., Ahmad, Neelour, Hoffman, Karen E., Joyner, Melissa M., Mitchell, Melissa P., Poenisch, Falk, Smith, Benjamin D., Strom, Eric A., Vallabhaneni, Srilakshmi, Cheng, Richard, Kang, Kylie H., Kim, H. Katherine, Kim, Janice N., Wang, Waylene A., Wong, Tony, Bosch, Walter, Mitchell, Joshua, Straube, William, Zoberi, Imran, Balanescu, Dinu, Chen, Peter Y., Dilworth, Joshua T., Ding, Xuanfeng, Donisan, Teodora, Hamstra, Daniel A., Daniella Dang, Phuong, Katz, Stanford, Wang, Chiachien J., Terry Wu, Hahn, Elizabeth A., Pugh, Stephanie L., Lu, Hien L., Vela, Alyssa M., Gillespie, Erin F., Nichols, Elizabeth M., Wright, Jean L., MacDonald, Shannon M., Cahlon, Oren, Baas, Carole, Braunstein, Lior Z., Fang, L. Christine, Freedman, Gary M., Jimenez, Rachel B., Kesslering, Christy M., Mishra, Mark V., Mutter, Robert W., Ohri, Nisha, Rosen, Lane R., Urbanic, James J., Jagsi, Reshma, Mitchell, Sandra A., Bekelman, Justin E., and Cella, David

Published
2024
Full Text
View/download PDF

4. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902

Author

Hamstra, Daniel A, Pugh, Stephanie L, Lepor, Herbert, Rosenthal, Seth A, Pienta, Kenneth J, Gomella, Leonard, Peters, Christopher, D'Souza, David Paul, Zeitzer, Kenneth L, Jones, Christopher U, Hall, William A, Horwitz, Eric, Pisansky, Thomas M, Souhami, Luis, Hartford, Alan C, Dominello, Michael, Feng, Felix, and Sandler, Howard M

Subjects
Clinical Research, Aged, Androgen Antagonists, Follow-Up Studies, Humans, Male, Multivariate Analysis, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Prostate, Prostate-Specific Antigen, Prostatic Neoplasms, Risk, Survival Analysis, Prostate cancer, Gleason score, Distant metastasis, Radiation therapy, Other Physical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Background/purposeStratification of Gleason score (GS) into three categories (2-6, 7, and 8-10) may not fully utilize its prognostic discrimination, with Gleason pattern 5 (GP5) previously identified as an independent adverse factor.Materials/methodsPatients treated on RTOG 9202 (n = 1292) or RTOG 9902 (n = 378) were pooled and assessed for association of GS and GP5 on biochemical failure (BF), local failure (LF), distant metastasis (DM), and overall survival (OS). Fine and Gray's regression and cumulative incidence methods were used for univariate and multivariate analyses.ResultsWith median follow-up of 9.4 years, patients with GS 8-10 with GP5 had worse outcome than GS 4 + 4 for DM on both RTOG9202 (p = 0.038) and RTOG9902 (p

Published
2019

10. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life

Author

Gay, Hiram A, Sanda, Martin G, Liu, Jingxia, Wu, Ningying, Hamstra, Daniel A, Wei, John T, Dunn, Rodney L, Klein, Eric A, Sandler, Howard M, Saigal, Christopher S, Litwin, Mark S, Kuban, Deborah A, Hembroff, Larry, Regan, Meredith M, Chang, Peter, Consortium, Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment, Regan, Meredith, Hamstra, Dan, Dunn, Rodney, Northouse, Laurel, Wood, David, Ciezki, Jay, Michalski, Jeff, Andriole, Gerald, Saigal, Christopher, Greenfield, Thomas, Pisters, Louis, Kuban, Deborah, Sandler, Howard, Hu, Jim, Kibel, Adam, Dahl, Douglas, Zietman, Anthony, Kaplan, Irving, Wagner, Andrew, and Michalski, Jeff M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Trials and Supportive Activities, Aging, Prostate Cancer, Urologic Diseases, Clinical Research, Aged, Aged, 80 and over, Androgen Antagonists, Body Weight, Brachytherapy, Breast, Chi-Square Distribution, Combined Modality Therapy, Depression, Erectile Dysfunction, Fatigue, Hot Flashes, Humans, Male, Middle Aged, Neoadjuvant Therapy, Orgasm, Penile Erection, Prospective Studies, Prostate-Specific Antigen, Prostatic Neoplasms, Quality of Life, Surveys and Questionnaires, Time Factors, Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium, Other Physical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Theoretical and computational chemistry, Medical and biological physics
Abstract

PurposeThe long-term effects of neoadjuvant androgen deprivation therapy (NADT) with radiation therapy on participant-reported health-related quality of life (HRQOL) have not been characterized in prospective multicenter studies. We evaluated HRQOL for 2 years among participants undergoing radiation therapy (RT) with or without NADT for newly diagnosed, early-stage prostate cancer.Methods and materialsWe analyzed longitudinal cohort data from the Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium to ascertain the HRQOL trajectory of men receiving NADT with external beam RT (EBRT) or brachytherapy. HRQOL was measured using the expanded prostate cancer index composite 26-item questionnaire at 2, 6, 12, and 24 months after the initiation of NADT. We used the χ2 or Fisher exact test to compare the shift in percentages between groups that did or did not receive NADT. Analyses were conducted at the 2-sided 5% significance level.ResultsFor subjects receiving EBRT, questions regarding the ability to have an erection, ability to reach an orgasm, quality of erections, frequency of erections, ability to function sexually, and lack of energy were in a significantly worse dichotomized category for the patients receiving NADT. Comparing the baseline versus 24-month outcomes, 24%, 23%, and 30% of participants receiving EBRT plus NADT shifted to the worse dichotomized category for the ability to reach an orgasm, quality of erections, and ability to function sexually compared with 14%, 13%, and 16% in the EBRT group, respectively.ConclusionsCompared with baseline, at 2 years, participants receiving NADT plus EBRT compared with EBRT alone had worse HRQOL, as measured by the ability to reach orgasm, quality of erections, and ability to function sexually. However, no difference was found in the ability to have an erection, frequency of erections, overall sexual function, hot flashes, breast tenderness/enlargement, depression, lack of energy, or change in body weight. The improved survival in intermediate- and high-risk patients receiving NADT and EBRT necessitates pretreatment counseling of the HRQOL effect of NADT and EBRT.

Published
2017

11. Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment

Author

Chang, Peter, Regan, Meredith M, Ferrer, Montserrat, Guedea, Ferran, Patil, Dattatraya, Wei, John T, Hembroff, Larry A, Michalski, Jeff M, Saigal, Chris S, Litwin, Mark S, Hamstra, Daniel A, Kaplan, Irving D, Ciezki, Jay P, Klein, Eric A, Kibel, Adam S, Sandler, Howard M, Dunn, Rodney L, Crociani, Catrina M, Sanda, Martin G, and Consortium, PROST-QA

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Prostate Cancer, Urologic Diseases, Clinical Trials and Supportive Activities, Cancer, Clinical Research, Renal and urogenital, Aged, Brachytherapy, Cost of Illness, Follow-Up Studies, Humans, Lower Urinary Tract Symptoms, Male, Middle Aged, Prospective Studies, Prostatectomy, Prostatic Neoplasms, Quality of Life, Treatment Outcome, prostatic neoplasms, quality of life, outcome assessment, surveys and questionnaires, patient-centered care, PROST-QA Consortium, Urology & Nephrology, Clinical sciences
Abstract

PurposeHarms of prostate cancer treatment on urinary health related quality of life have been thoroughly studied. In this study we evaluated not only the harms but also the potential benefits of prostate cancer treatment in relieving the pretreatment urinary symptom burden.Materials and methodsIn American (1,021) and Spanish (539) multicenter prospective cohorts of men with localized prostate cancer we evaluated the effects of radical prostatectomy, external radiotherapy or brachytherapy in relieving pretreatment urinary symptoms and in inducing urinary symptoms de novo, measured by changes in urinary medication use and patient reported urinary bother.ResultsUrinary symptom burden improved in 23% and worsened in 28% of subjects after prostate cancer treatment in the American cohort. Urinary medication use rates before treatment and 2 years after treatment were 15% and 6% with radical prostatectomy, 22% and 26% with external radiotherapy, and 19% and 46% with brachytherapy, respectively. Pretreatment urinary medication use (OR 1.4, 95% CI 1.0-2.0, p = 0.04) and pretreatment moderate lower urinary tract symptoms (OR 2.8, 95% CI 2.2-3.6) predicted prostate cancer treatment associated relief of baseline urinary symptom burden. Subjects with pretreatment lower urinary tract symptoms who underwent radical prostatectomy experienced the greatest relief of pretreatment symptoms (OR 4.3, 95% CI 3.0-6.1), despite the development of deleterious de novo urinary incontinence in some men. The magnitude of pretreatment urinary symptom burden and beneficial effect of cancer treatment on those symptoms were verified in the Spanish cohort.ConclusionsMen with pretreatment lower urinary tract symptoms may experience benefit rather than harm in overall urinary outcome from primary prostate cancer treatment. Practitioners should consider the full spectrum of urinary symptom burden evident before prostate cancer treatment in treatment decisions.

Published
2017

12. Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial

Author

Quinn, Thomas J., Daignault-Newton, Stephanie, Bosch, Walter, Mariados, Neil, Sylvester, John, Shah, Dhiren, Gross, Eric, Hudes, Richard, Beyer, David, Kurtzman, Steven, Bogart, Jeffrey, Hsi, R. Alex, Kos, Michael, Ellis, Rodney, Logsdon, Mark, Zimberg, Shawn, Forsythe, Kevin, Zhang, Hong, Soffen, Edward, Francke, Patrick, Mantz, Constantine, DeWeese, Theodore, Gay, Hiram A., Michalski, Jeff, and Hamstra, Daniel A.

Published
2020
Full Text
View/download PDF

13. VA-Radiation Oncology Quality Surveillance Program

Author

Hagan, Michael, Kapoor, Rishabh, Michalski, Jeff, Sandler, Howard, Movsas, Benjamin, Chetty, Indrin, Lally, Brian, Rengan, Ramesh, Robinson, Cliff, Rimner, Andreas, Simone, Charles, Timmerman, Robert, Zelefsky, Michael, DeMarco, John, Hamstra, Daniel, Lawton, Colleen, Potters, Louis, Valicenti, Richard, Mutic, Sasa, Bosch, Walter, Abraham, Christopher, Caruthers, Douglas, Brame, Ryan, Palta, Jatinder R., Sleeman, William, and Nalluri, Joseph

Published
2020
Full Text
View/download PDF

14. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.

Author

Zhang, Yu, Kothari, Vishal, Evans, Joseph, Jackson, William, Chen, Wei, Johnson, Skyler, Luczak, Connor, Wang, Shaomeng, Hamstra, Daniel, and Feng, Felix

Subjects
Androgen Antagonists, Animals, Antineoplastic Agents, Apoptosis, Cell Line, Tumor, DNA Damage, Disease Models, Animal, Drug Resistance, Neoplasm, Humans, Indoles, Male, Prostatic Neoplasms, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-mdm2, Radiation Tolerance, Radiation, Ionizing, Spiro Compounds, Tumor Suppressor Protein p53, Xenograft Model Antitumor Assays
Abstract

PURPOSE: Increased murine double minute 2 (MDM2) expression, independent of p53 status, is associated with increased cancer-specific mortality for men with prostate cancer treated with radiotherapy. We assessed MI-219, a small molecule inhibitor of MDM2 with improved pharmacokinetics over nutlin-3, for sensitization of prostate cancer cells to radiotherapy and androgen deprivation therapy, a standard treatment option for men with high-risk prostate cancer. EXPERIMENTAL DESIGN: The effect of MDM2 inhibition by MI-219 was assessed in vitro and in vivo with mouse xenograft models across multiple prostate cancer cell lines containing varying p53 functional status. RESULTS: MDM2 inhibition by MI-219 resulted in dose- and time-dependent p53 activation and decreased clonogenic cell survival after radiation in a p53-dependent manner. Mechanistically, radiosensitization following inhibition of MDM2 was largely the result of p53-dependent increases in apoptosis and DNA damage as evidenced by Annexin V flow cytometry and γ-H2AX foci immunofluorescence. Similarly, treatment with MI-219 enhanced response to antiandrogen therapy via a p53-dependent increase in apoptotic cell death. Lastly, triple therapy with radiation, androgen deprivation therapy, and MI-219 decreased xenograft tumor growth compared with any single- or double-agent treatment. CONCLUSION: MDM2 inhibition with MI-219 results in p53-dependent sensitization of prostate cancer cells to radiation, antiandrogen therapy, and the combination. These findings support MDM2 small molecule inhibitor therapy as a therapy intensification strategy to improve clinical outcomes in high-risk localized prostate cancer. TRANSLATIONAL RELEVANCE: The combination of radiotherapy and androgen deprivation therapy is a standard treatment option for men with high-risk prostate cancer. Despite improvements in outcomes when androgen deprivation therapy is added to radiation, men with high-risk prostate cancer have significant risk for disease recurrence, progression, and even death within the first 10 years following treatment. We demonstrate that treatment with MI-219 (an inhibitor of MDM2) results in prostate cancer cell sensitization to radiation and androgen deprivation therapy in vitro and in vivo. Triple therapy with MI-219, radiation, and androgen deprivation therapy dramatically decreased tumor growth compared with any single- or double-agent therapy. These findings provide evidence that inhibition of MDM2 is a viable means by which to enhance the efficacy of both radiation and androgen deprivation therapy and thereby improve outcomes in the treatment of prostate cancer. As such, further investigation is warranted to translate these findings to the clinical setting.

Published
2016

15. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902

Author

Hamstra, Daniel A., Pugh, Stephanie L., Lepor, Herbert, Rosenthal, Seth A., Pienta, Kenneth J., Gomella, Leonard, Peters, Christopher, D'Souza, David Paul, Zeitzer, Kenneth L., Jones, Christopher U., Hall, William A., Horwitz, Eric, Pisansky, Thomas M., Souhami, Luis, Hartford, Alan C., Dominello, Michael, Feng, Felix, and Sandler, Howard M.

Published
2019
Full Text
View/download PDF

16. Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413

Author

Hamstra, Daniel A, Bae, Kyounghwa, Hanks, Gerald, Hu, Chen, Shipley, William U, Pan, Charlie C, Roach, Mack, Lawton, Colleen A, and Sandler, Howard M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Urologic Diseases, Aged, Aged, 80 and over, Humans, Kallikreins, Male, Middle Aged, Prognosis, Proportional Hazards Models, Prostate-Specific Antigen, Prostatic Neoplasms, Radiotherapy, Treatment Failure, Treatment Outcome, prostate-specific antigen, prostate-specific antigen failure, radiotherapy, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundBiochemical failure (BF) after radiation therapy is defined on the basis of a rising prostate-specific antigen (PSA) level (A1 failure) or any event that prompts the initiation of salvage androgen-deprivation therapy without PSA failure (A2). It was hypothesized that A2 failure may have a different prognosis.MethodsData for 2799 eligible patients from Radiation Therapy Oncology Group (RTOG) 9202 and RTOG 9413 were analyzed. BF was defined according to the 1997 American Society for Therapeutic Radiology and Oncology consensus definition as A1 for PSA failure or as A2 for the start of salvage hormone therapy before 3 consecutive PSA rises.ResultsRates of all-cause mortality (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.5-2.0; P

Published
2015

20. Neoadjuvant Androgen Deprivation Therapy Leads to Immediate Impairment of Vitality/Hormonal and Sexual Quality of Life: Results of a Multicenter Prospective Study

Author

Gay, Hiram Alberto, Michalski, Jeff M, Hamstra, Daniel A, Wei, John T, Dunn, Rodney L, Klein, Eric A, Sandler, Howard M, Saigal, Chris, Litwin, Mark, Kuban, Deborah, Hembroff, Larry, Chang, Peter, Sanda, Martin G, and Consortium, PROSTQA

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Urologic Diseases, Aging, Prostate Cancer, Cancer, Biopsy, Needle, Humans, Image-Guided Biopsy, Male, Prospective Studies, Prostatic Neoplasms, Quality of Life, Unnecessary Procedures, PROSTQA Consortium, Urology & Nephrology, Clinical sciences
Abstract

ObjectiveTo evaluate the immediate effects of neoadjuvant androgen deprivation therapy (NADT) on health-related quality of life (HRQOL) among patients undergoing radiation therapy (RT) for newly diagnosed prostate cancer.MethodsThe Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium is a prospective multi-institutional study. HRQOL is measured with the Expanded Prostate Cancer Index Composite-26 questionnaire. Differences in patient-reported HRQOL were observed between pretreatment and 2 months after NADT start (and before definitive RT) with significant differences evaluated by paired t test.ResultsFrom among 450 patients who completed the Expanded Prostate Cancer Index Composite-26 before and 2 months after NADT start, 71 received NADT before proceeding with definitive RT. Patients receiving NADT experienced significant impairment in vitality/hormonal (P

Published
2013

23. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life

Author

Jackson, William C., Dess, Robert T., Litzenberg, Dale W., Li, Pin, Schipper, Matthew, Rosenthal, Seth A., Chang, Garrick C., Horwitz, Eric M., Price, Robert A., Michalski, Jeff M., Gay, Hiram A., Wei, John T., Feng, Mary, Feng, Felix Y., Sandler, Howard M., Wallace, Robert E., Spratt, Daniel E., and Hamstra, Daniel A.

Published
2018
Full Text
View/download PDF

24. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial

Author

Hamstra, Daniel A., Mariados, Neil, Sylvester, John, Shah, Dhiren, Gross, Eric, Hudes, Richard, Beyer, David, Kurtzman, Steven, Bogart, Jeffrey, Hsi, R. Alex, Kos, Michael, Ellis, Rodney, Logsdon, Mark, Zimberg, Shawn, Forsythe, Kevin, Zhang, Hong, Soffen, Edward, Francke, Patrick, Mantz, Constantine, Rossi, Peter, DeWeese, Theodore, Daignault-Newton, Stephanie, Fischer-Valuck, Benjamin W., Chundury, Anupama, Gay, Hiram A., Bosch, Walter, and Michalski, Jeff

Published
2018
Full Text
View/download PDF

25. Prostate intrafraction translation margins for real-time monitoring and correction strategies.

Author

Litzenberg, Dale W, Balter, James M, Hadley, Scott W, Hamstra, Daniel A, Willoughby, Twyla R, Kupelian, Patrick A, Djemil, Toufik, Mahadevan, Arul, Jani, Shirish, Weinstein, Geoffrey, Solberg, Timothy, Enke, Charles, Levine, Lisa, and Sandler, Howard M

Subjects
Oncology and Carcinogenesis
Abstract

The purpose of this work is to determine appropriate radiation therapy beam margins to account for intrafraction prostate translations for use with real-time electromagnetic position monitoring and correction strategies. Motion was measured continuously in 35 patients over 1157 fractions at 5 institutions. This data was studied using van Herk's formula of (αΣ + γσ') for situations ranging from no electromagnetic guidance to automated real-time corrections. Without electromagnetic guidance, margins of over 10 mm are necessary to ensure 95% dosimetric coverage while automated electromagnetic guidance allows the margins necessary for intrafraction translations to be reduced to submillimeter levels. Factors such as prostate deformation and rotation, which are not included in this analysis, will become the dominant concerns as margins are reduced. Continuous electromagnetic monitoring and automated correction have the potential to reduce prostate margins to 2-3 mm, while ensuring that a higher percentage of patients (99% versus 90%) receive a greater percentage (99% versus 95%) of the prescription dose.

Published
2012

26. Prediction of Erectile Function Following Treatment for Prostate Cancer

Author

Alemozaffar, Mehrdad, Regan, Meredith M, Cooperberg, Matthew R, Wei, John T, Michalski, Jeff M, Sandler, Howard M, Hembroff, Larry, Sadetsky, Natalia, Saigal, Christopher S, Litwin, Mark S, Klein, Eric, Kibel, Adam S, Hamstra, Daniel A, Pisters, Louis L, Kuban, Deborah A, Kaplan, Irving D, Wood, David P, Ciezki, Jay, Dunn, Rodney L, Carroll, Peter R, and Sanda, Martin G

Subjects
Cancer, Urologic Diseases, Rehabilitation, Prostate Cancer, Clinical Research, Aging, Aged, Brachytherapy, Erectile Dysfunction, Forecasting, Humans, Longitudinal Studies, Male, Middle Aged, Models, Theoretical, Outcome Assessment, Health Care, Penile Erection, Prostatectomy, Prostatic Neoplasms, Quality of Life, Radiation Injuries, Medical and Health Sciences, General & Internal Medicine
Abstract

ContextSexual function is the health-related quality of life (HRQOL) domain most commonly impaired after prostate cancer treatment; however, validated tools to enable personalized prediction of erectile dysfunction after prostate cancer treatment are lacking.ObjectiveTo predict long-term erectile function following prostate cancer treatment based on individual patient and treatment characteristics.DesignPretreatment patient characteristics, sexual HRQOL, and treatment details measured in a longitudinal academic multicenter cohort (Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment; enrolled from 2003 through 2006), were used to develop models predicting erectile function 2 years after treatment. A community-based cohort (community-based Cancer of the Prostate Strategic Urologic Research Endeavor [CaPSURE]; enrolled 1995 through 2007) externally validated model performance. Patients in US academic and community-based practices whose HRQOL was measured pretreatment (N = 1201) underwent follow-up after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer. Sexual outcomes among men completing 2 years' follow-up (n = 1027) were used to develop models predicting erectile function that were externally validated among 1913 patients in a community-based cohort.Main outcome measuresPatient-reported functional erections suitable for intercourse 2 years following prostate cancer treatment.ResultsTwo years after prostate cancer treatment, 368 (37% [95% CI, 34%-40%]) of all patients and 335 (48% [95% CI, 45%-52%]) of those with functional erections prior to treatment reported functional erections; 531 (53% [95% CI, 50%-56%]) of patients without penile prostheses reported use of medications or other devices for erectile dysfunction. Pretreatment sexual HRQOL score, age, serum prostate-specific antigen level, race/ethnicity, body mass index, and intended treatment details were associated with functional erections 2 years after treatment. Multivariable logistic regression models predicting erectile function estimated 2-year function probabilities from as low as 10% or less to as high as 70% or greater depending on the individual's pretreatment patient characteristics and treatment details. The models performed well in predicting erections in external validation among CaPSURE cohort patients (areas under the receiver operating characteristic curve, 0.77 [95% CI, 0.74-0.80] for prostatectomy; 0.87 [95% CI, 0.80-0.94] for external radiotherapy; and 0.90 [95% CI, 0.85-0.95] for brachytherapy).ConclusionStratification by pretreatment patient characteristics and treatment details enables prediction of erectile function 2 years after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer.

Published
2011

28. Noninvasive Real-Time Imaging of Apoptosis

Author

Laxman, Bharathi, Hall, Daniel E., Bhojani, Mahaveer Swaroop, Hamstra, Daniel A., Chenevert, Thomas L., Ross, Brian D., and Rehemtulla, Alnawaz

Published
2002

29. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life

Author

Regan, Meredith, Hembroff, Larry, Wei, John T., Hamstra, Dan, Dunn, Rodney, Northouse, Laurel, Wood, David, Klein, Eric A., Ciezki, Jay, Michalski, Jeff, Andriole, Gerald, Litwin, Mark S., Saigal, Christopher, Greenfield, Thomas, Pisters, Louis, Kuban, Deborah, Sandler, Howard, Hu, Jim, Kibel, Adam, Dahl, Douglas, Zietman, Anthony, Chang, Peter, Kaplan, Irving, Wagner, Andrew, Sanda, Martin G., Gay, Hiram A., Liu, Jingxia, Wu, Ningying, Hamstra, Daniel A., Dunn, Rodney L., Sandler, Howard M., Saigal, Christopher S., Kuban, Deborah A., Regan, Meredith M., and Michalski, Jeff M.

Published
2017
Full Text
View/download PDF

30. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial

Author

Hamstra, Daniel A., Mariados, Neil, Sylvester, John, Shah, Dhiren, Karsh, Lawrence, Hudes, Richard, Beyer, David, Kurtzman, Steven, Bogart, Jeffrey, Hsi, R. Alex, Kos, Michael, Ellis, Rodney, Logsdon, Mark, Zimberg, Shawn, Forsythe, Kevin, Zhang, Hong, Soffen, Edward, Francke, Patrick, Mantz, Constantine, Rossi, Peter, DeWeese, Theodore, Daignault-Newton, Stephanie, Fischer-Valuck, Benjamin W., Chundury, Anupama, Gay, Hiram, Bosch, Walter, and Michalski, Jeff

Published
2017
Full Text
View/download PDF

33. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy—A Multi-Institutional Observational Study

Author

Pisansky, Thomas M., Agrawal, Shree, Hamstra, Daniel A., Koontz, Bridget F., Liauw, Stanley L., Efstathiou, Jason A., Michalski, Jeff M., Feng, Felix Y., Abramowitz, Matthew C., Pollack, Alan, Anscher, Mitchell S., Moghanaki, Drew, Den, Robert B., Stephans, Kevin L., Zietman, Anthony L., Lee, W. Robert, Kattan, Michael W., Stephenson, Andrew J., and Tendulkar, Rahul D.

Published
2016
Full Text
View/download PDF

34. Six-year-old male with acute eye swelling and drainage

Author

Sharrak, Aryana, Bergsman, Christopher, and Hamstra, Daniel A.

Subjects
Sulbactam, Antihistamines, Antibiotics, Health, Health care industry
Abstract

THE CASE A 6-year-old boy presented to his pediatrician with clear drainage from his left eye for 1 to 2 days. Of note, the patient was not immunized due to [...]

Published
2021

35. PD15-02 LONG-TERM HEALTH RELATED QUALITY OF LIFE IN PROSTATE CANCER PATIENTS REQUIRING RADIOTHERAPY AFTER RADICAL PROSTATECTOMY

Author

Olsen, T. Anders, primary, Patel, Sagar, additional, Patil, Dattatraya, additional, Alperti, Louis, additional, Smith, Joseph, additional, Saigal, Christopher, additional, Litwin, Mark, additional, Hu, Jim, additional, Cooperberg, Matthew, additional, Carroll, Peter, additional, Klein, Eric, additional, Ciezki, Jay, additional, Kibel, Adam, additional, Andriole, Gerald, additional, Michalski, Jeff, additional, Han, Misop, additional, Partin, Alan, additional, Wood, David, additional, Hembroff, Larry, additional, Spratt, Daniel, additional, Wei, John, additional, Sandler, Howard, additional, Hamstra, Daniel, additional, Pisters, Louis, additional, Kuban, Deborah, additional, Regan, Meredith, additional, Wagner, Andrew, additional, Kaplan, Irving, additional, Crociani, Catrina, additional, Sanda, Martin, additional, and Chang, Peter, additional

Published
2023
Full Text
View/download PDF

40. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding

Author

Lee, Jae Y., Daignault-Newton, Stephanie, Heath, Gerard, Scarlett, Sarah, Sanda, Martin G., Chang, Peter, Regan, Meredith M., Michalski, Jeff M., Sandler, Howard M., Feng, Felix Y., Kuban, Deborah A., Zietman, Anthony L., Ciezki, Jay P., Kaplan, Irving D., Crociani, Catrina, McLaughlin, William P., Mantz, Constantine A., Finkelstein, Steven E., Suy, Simeng, Collins, Sean P., Garin, Olatz, Ferrer, Montserrat, Hamstra, Daniel A., and Spratt, Daniel E.

Published
2016
Full Text
View/download PDF

44. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902

Author

Rosenthal, Seth A., Hunt, Daniel, Sartor, A. Oliver, Pienta, Kenneth J., Gomella, Leonard, Grignon, David, Rajan, Raghu, Kerlin, Kevin J., Jones, Christopher U., Dobelbower, Michael, Shipley, William U., Zeitzer, Kenneth, Hamstra, Daniel A., Donavanik, Viroon, Rotman, Marvin, Hartford, Alan C., Michalski, Jeffrey, Seider, Michael, Kim, Harold, Kuban, Deborah A., Moughan, Jennifer, and Sandler, Howard

Published
2015
Full Text
View/download PDF

45. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy

Author

Mariados, Neil, Sylvester, John, Shah, Dhiren, Karsh, Lawrence, Hudes, Richard, Beyer, David, Kurtzman, Steven, Bogart, Jeffrey, Hsi, R. Alex, Kos, Michael, Ellis, Rodney, Logsdon, Mark, Zimberg, Shawn, Forsythe, Kevin, Zhang, Hong, Soffen, Edward, Francke, Patrick, Mantz, Constantine, Rossi, Peter, DeWeese, Theodore, Hamstra, Daniel A., Bosch, Walter, Gay, Hiram, and Michalski, Jeff

Published
2015
Full Text
View/download PDF

47. Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series

Author

Koloff, Zachary B., Hamstra, Daniel A., Wei, John T., Montgomery, Jeffrey S., Tomlins, Scott A., Wu, Angela J., Morgan, Todd M., Siddiqui, Javed, Paich, Kellie, Chinnaiyan, Arul M., Feng, Felix Y., Weizer, Alon Z., Kunju, Lakshmi P., Hollenbeck, Brent K., Miller, David C., Palapattu, Ganesh S., and Mehra, Rohit

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results